Back to search

Article

Plasmodium falciparum genetic factors rather than the hosts' are likely to drive resistance to acts in ghana.

2020-01-21

Abstract excerpt

<h4>Background: </h4> Artemisinin-based Combination Therapy (ACT), a combination of a fast-acting artemisinin derivative and a relatively slow-acting partner drug, is used for malaria treatment in disease-endemic areas. The ACT partner drugs, currently used in Ghana are lumefantrine, amodiaquine, and piperaquine. Plasmodium falciparum isolates with reduced susceptibility to these partner drugs may affect treatment...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0885732e-2078-5fea-b2ce-74fb44999edb
DOI
10.21203/rs.2.21377/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Plasmodium falciparum genetic factors rather than the hosts' are likely to drive resistance to acts in ghana.DOI 10.21203/rs.2.21377/v1
Plasmodium falciparum genetic factors rather than host factors are likely to drive resistance to ACT in GhanaSemantic proximity
Prevalence of chloroquine and antifolate drug resistance alleles in Plasmodium falciparum clinical isolates from three areas in GhanaSemantic proximity
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malariaSemantic proximity
Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance.Semantic proximity
Xeno-monitoring of molecular drivers of artemisinin and partner drug resistance in <i>P. falciparum</i> populations in malaria vectors across CameroonSemantic proximity
Xeno-monitoring of molecular drivers of artemisinin and partner drug resistance in P. falciparum populations in malaria vectors across CameroonSemantic proximity
The pharmacogenetics of antimalaria artemisinin combination therapy.Semantic proximity
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.Semantic proximity
Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug PrimaquineSemantic proximity
Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance.Semantic proximity
Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa.Semantic proximity
Molecular markers in plasmodium falciparum linked to resistance to anti-malarial drugs in samples imported from Africa over an eight-year period (2002-2010): impact of the introduction of artemisinin combination therapy.Semantic proximity
Select a neighboring publication to make it the new centre.